SAR443820 for treating amyotrophic lateral sclerosis (ALS)

SAR443620 is in phase II clinical development for the treatment of patients with amyotrophic lateral sclerosis (ALS), a form of motor neurone disease. ALS is a progressive disease where the nerve cells responsible for sending instructions to the muscles gradually deteriorate, leading to weakness, muscle wasting and paralysis. ALS is a debilitating and fatal disease. The initial symptoms of ALS can be varied but begin in the muscles that control speech and swallowing or in the hands, arms, legs or feet. Not all people with ALS experience the same symptoms or the same sequences or patterns of progression. However, progressive muscle weakness and paralysis are universally experienced. Currently, there is no cure for ALS and the treatments available have no profound effect on survival.